Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA Approves a Nasal Antihistamine for Nonprescription Use


SILVER SPRING, Md., June 17, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch. The FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis?commonly known as allergies?for adults and children six years of age and older.

"Seasonal and perennial allergies affect millions of Americans every year, causing them to experience symptoms of nasal congestion, runny nose, sneezing and more," said Theresa M. Michele, M.D., director of the office of nonprescription drugs in the FDA's Center for Drug Evaluation and Research. "Today's approval provides individuals an option for a safe and effective nasal antihistamine without requiring the assistance of a healthcare provider."

For a drug to switch from prescription to nonprescription status, the data provided must demonstrate that the drug is safe and effective for use in self-medication as directed in proposed labeling. The manufacturer must show that consumers can understand how to use the drug safely and effectively without the supervision of a healthcare professional. This approval is a first-in-class switch for a nasal antihistamine and is considered a partial switch because the 0.1% strength, which includes the perennial allergy indication for children 6 months to 6 years old and seasonal allergy indication for children 2 to 6 years old, will remain prescription based.

Azelastine can cause drowsiness. The label warns that consumers using this product should avoid alcoholic drinks and be careful when driving a motor vehicle or operating machinery. Using azelastine nasal spray with alcohol, sedatives, or tranquilizers may increase drowsiness.

The FDA granted the approval of nonprescription Astepro to Bayer Healthcare LLC.

Media Contact: Courtney Rhodes, 202-281-5237
Consumer Inquiries: Email or 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

 

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 20:50
Overture.law, the nation's leading attorney-to-attorney referral platform, launches their transformative new product, Inner Circles. This groundbreaking product empowers attorneys, law schools, bar associations, and affinity groups to build private...

at 20:09
BASIS Charter Schools proudly announce that two of its exceptional students have been named 2024 U.S. Presidential Scholars by the U.S. Department of Education. Matteo N. Huish from BASIS Mesa and Sruti Peddi from BASIS Scottsdale have been...

at 20:00
Kemal Hawa, co-chair of the Digital Infrastructure, Data Center and Cloud Computing Practice of global law firm Greenberg Traurig, LLP, will moderate a panel at DICE East 2024 May 22 in Reston, Virginia. Hawa, a member of the firm's Washington,...

at 19:45
WIO LLC, parent company of the global TV broadcast airings platform, WIOprotm, has announced a new strategic agreement with Gracenote, the global content data business unit of Nielsen, to address the longstanding challenge of accurately tracking and...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...



News published on and distributed by: